Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero

Abstract

Keliximab is a human-cynomolgus monkey chimeric (Primatized) monoclonal antibody with specificity for human and chimpanzee CD4. As the preclinical safety assessment of biopharmaceuticals requires evaluation in pharmacologically responsive species, comprehensive toxicology studies, including reproductive toxicity, of this antibody were conducted in a human CD4 transgenic mouse model. The reproductive toxicology studies included a preand postnatal development study that incorporated immunotoxicological evaluation of offspring (F1) mice. The potential effects of exposure to treating maternal mice (F0) with keliximab during pregnancy and lactation on offspring viability, physical growth, neurobehavioral development, reproductive function, lymphoid tissue morphological structure, lymphocyte subsets and host resistance to Candida albicans infection were assessed. The results showed no impairment of these functions. The use of F1 transgenic mice in study with keliximab provides an example of a novel practical approach to assess developmental immunotoxicity within a study of preand postnatal development designed in accordance with ICH Guidelines.

Keywords

anti-CD4 antibody C. albicans infection lymphoid tissues offspring transgenic mice

References

Ellmeier W , Sawada S , Littman DR . The regulation of CD4 and CD8 coreceptor gene expression during T cell development . Annu Rev Immunol 1999; 17: 523–54 .

Choy EH , Kingsley GH , Panayi GS . Anti-CD4 monoclonal antibodies in rheumatoid arthritis . Springer Semin Immunopathol 1998; 20: 261–73 .

Kon OM , Kay AB . T cells and chronic asthma . Int Arch Allergy Immunol 1999; 118: 133–35 .

Anderson D , Chambers K , Hanna N , et al. A primatized2 MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo: characterization of a MAb (IDEC-CE9.1) to human CD4 . Clin Immunol Immunopathol 1997; 84: 73–84 .

Killeen N , Sawada S , Littman DR . Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4 . EMBO J 1993; 12: 1547–53 .

ICH Reference: US Food and Drug Administration. International conference on harmonisation; Guideline on detection of toxicology to reproduction for medicinal products; Availability . Federal Register 1994; Vol. 59, No. 183, pp. 48746–52 . See also Amendment, Federal Register 1996; Vol. 61, No. 67, pp. 15359–61.

Bugelski PJ , Herzyk DJ , Rehm S , et al. Preclinical development of Keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies . Hum Exp Toxicol 2000; 19: 230–43 .

Zuniga-Pflucker JC , McCarthy SA , Weston M , Longo DL , Singer A , Kruisbeek AM . Role of CD4 in thymocyte selection and maturation . J Exp Med 1989; 169: 2085–96 .

Miller RK , Koszalka TR , Brent RL . The transport of molecules across placental membranes. In Poste G , Nicolson GL eds. The cell surface in animal embryogenesis and development. Amsterdam: Elsevier /NorthHolland Biomedical Press , 1976: 145–223.

10.

Herzyk DJ , Gore ER , Polsky R , et al. Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice . Infect Immun 2001; 69: 1032–43 .

11.

Sharma A , Davis CB , Tobia LP , et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4 . J Pharmacol Exp Ther 2000; 293: 33–41 .

12.

Wier PJ , Guerriero FJ , Walker RF . Implementation of a primary screen for developmental neurotoxicity . Fundam Appl Toxicol 1989; 13: 118–36 .

13.

Gossett KA , Narayanan PK , Williams DM , et al. Flow cytometry in the preclinical development of biopharmaceuticals . Toxicol Pathol 1999; 27: 32–37 .

14.

Herzyk DJ , Ruggieri EV , Cunningham L , et al. Singleorganism model of host defense against infection: a novel immunotoxicologic approach to evaluate immunomodulatory drugs . Toxicol Pathol 1997; 25: 351–62 .

15.

Cammarota G , Scheirle A , Takacs B , et al. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules . Nature 1992; 356: 799–801 .

16.

Clayton LK , Sieh M , Pious DA , Reinherz EL . Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding . Nature 1989; 339: 548–51 .

17.

Fleming AL , Field EH , Tolaymat N , Cowdery JS . Age influences recovery of systemic and mucosal immune responses following acute depletion of CD4 T cells . Clin Immunol Immunopharmacol 1993; 69: 285–91 .